Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 49946 | 4.58 |
09:34 ET | 8185 | 4.545 |
09:36 ET | 36232 | 4.535 |
09:38 ET | 4846 | 4.51 |
09:39 ET | 31194 | 4.5499 |
09:41 ET | 34101 | 4.5302 |
09:43 ET | 3466 | 4.53 |
09:45 ET | 6633 | 4.53 |
09:48 ET | 10873 | 4.51 |
09:50 ET | 1663 | 4.515 |
09:52 ET | 2291 | 4.515 |
09:54 ET | 14152 | 4.535 |
09:56 ET | 11701 | 4.53 |
09:57 ET | 10546 | 4.52 |
09:59 ET | 19474 | 4.535 |
10:01 ET | 7951 | 4.5433 |
10:03 ET | 107819 | 4.565 |
10:06 ET | 28528 | 4.565 |
10:08 ET | 4303 | 4.56 |
10:10 ET | 24592 | 4.575 |
10:12 ET | 5668 | 4.575 |
10:14 ET | 43600 | 4.5765 |
10:15 ET | 14638 | 4.585 |
10:17 ET | 3316 | 4.59 |
10:19 ET | 8884 | 4.595 |
10:21 ET | 21368 | 4.62 |
10:24 ET | 71419 | 4.61 |
10:26 ET | 58497 | 4.615 |
10:28 ET | 7306 | 4.61 |
10:30 ET | 18411 | 4.6 |
10:32 ET | 32750 | 4.6 |
10:33 ET | 20921 | 4.605 |
10:35 ET | 131694 | 4.62 |
10:37 ET | 381869 | 4.645 |
10:39 ET | 27487 | 4.64 |
10:42 ET | 24682 | 4.645 |
10:44 ET | 17302 | 4.645 |
10:46 ET | 79609 | 4.655 |
10:48 ET | 60052 | 4.645 |
10:50 ET | 18707 | 4.66 |
10:51 ET | 32458 | 4.676 |
10:53 ET | 21604 | 4.675 |
10:55 ET | 134347 | 4.665 |
10:57 ET | 77155 | 4.66 |
11:00 ET | 66507 | 4.655 |
11:02 ET | 5209 | 4.655 |
11:04 ET | 1329 | 4.655 |
11:06 ET | 99211 | 4.71 |
11:08 ET | 100955 | 4.73 |
11:09 ET | 4719 | 4.725 |
11:11 ET | 23999 | 4.7371 |
11:13 ET | 58861 | 4.705 |
11:15 ET | 50514 | 4.725 |
11:18 ET | 61756 | 4.735 |
11:20 ET | 33623 | 4.73 |
11:22 ET | 12216 | 4.73 |
11:24 ET | 22115 | 4.725 |
11:26 ET | 8791 | 4.7163 |
11:27 ET | 97510 | 4.725 |
11:29 ET | 55517 | 4.725 |
11:31 ET | 64057 | 4.68 |
11:33 ET | 2377 | 4.685 |
11:36 ET | 31402 | 4.685 |
11:38 ET | 9157 | 4.67 |
11:40 ET | 2033 | 4.67 |
11:42 ET | 8432 | 4.665 |
11:44 ET | 15307 | 4.6492 |
11:45 ET | 21784 | 4.6428 |
11:47 ET | 24580 | 4.64 |
11:49 ET | 31696 | 4.635 |
11:51 ET | 23665 | 4.63 |
11:54 ET | 1201 | 4.63 |
11:56 ET | 5567 | 4.635 |
11:58 ET | 18276 | 4.635 |
12:00 ET | 8760 | 4.6312 |
12:02 ET | 22261 | 4.635 |
12:03 ET | 1749 | 4.63 |
12:05 ET | 39092 | 4.63 |
12:07 ET | 7447 | 4.626 |
12:09 ET | 3200 | 4.625 |
12:12 ET | 188790 | 4.645 |
12:14 ET | 5323 | 4.64 |
12:16 ET | 1100 | 4.645 |
12:18 ET | 6783 | 4.65 |
12:20 ET | 1916 | 4.645 |
12:21 ET | 3928 | 4.64 |
12:23 ET | 22871 | 4.635 |
12:25 ET | 8266 | 4.635 |
12:27 ET | 1200 | 4.63 |
12:30 ET | 8895 | 4.6301 |
12:32 ET | 64258 | 4.635 |
12:34 ET | 23239 | 4.625 |
12:36 ET | 10785 | 4.625 |
12:38 ET | 3199 | 4.6299 |
12:39 ET | 5812 | 4.625 |
12:41 ET | 7417 | 4.625 |
12:43 ET | 5796 | 4.62 |
12:45 ET | 1620 | 4.625 |
12:48 ET | 2271 | 4.625 |
12:50 ET | 35888 | 4.635 |
12:52 ET | 15197 | 4.625 |
12:54 ET | 5977 | 4.625 |
12:56 ET | 18859 | 4.615 |
12:57 ET | 16577 | 4.625 |
12:59 ET | 704 | 4.625 |
01:01 ET | 11898 | 4.62 |
01:03 ET | 1724 | 4.615 |
01:06 ET | 19380 | 4.615 |
01:08 ET | 9075 | 4.63 |
01:10 ET | 2699 | 4.63 |
01:12 ET | 7359 | 4.625 |
01:14 ET | 1753 | 4.63 |
01:15 ET | 60017 | 4.626 |
01:17 ET | 2738 | 4.6214 |
01:19 ET | 81961 | 4.63 |
01:21 ET | 30537 | 4.63 |
01:24 ET | 1270 | 4.635 |
01:26 ET | 93598 | 4.63 |
01:28 ET | 60161 | 4.63 |
01:30 ET | 5901 | 4.63 |
01:32 ET | 4596 | 4.63 |
01:33 ET | 6691 | 4.625 |
01:35 ET | 4065 | 4.625 |
01:37 ET | 2165 | 4.63 |
01:39 ET | 1650 | 4.63 |
01:42 ET | 2212 | 4.625 |
01:44 ET | 700 | 4.62 |
01:46 ET | 14886 | 4.63 |
01:48 ET | 111353 | 4.635 |
01:50 ET | 6246 | 4.64 |
01:51 ET | 13748 | 4.64 |
01:53 ET | 15431 | 4.64 |
01:55 ET | 8482 | 4.635 |
01:57 ET | 1836 | 4.64 |
02:00 ET | 9344 | 4.65 |
02:02 ET | 6090 | 4.64 |
02:04 ET | 18511 | 4.64 |
02:06 ET | 600 | 4.64 |
02:08 ET | 2300 | 4.64 |
02:09 ET | 1200 | 4.64 |
02:11 ET | 1801 | 4.64 |
02:13 ET | 2733 | 4.64 |
02:15 ET | 26232 | 4.64 |
02:18 ET | 2900 | 4.64 |
02:20 ET | 1754 | 4.6366 |
02:22 ET | 4031 | 4.64 |
02:24 ET | 624 | 4.64 |
02:26 ET | 1067 | 4.64 |
02:27 ET | 1592 | 4.64 |
02:29 ET | 1350 | 4.64 |
02:31 ET | 61253 | 4.63 |
02:33 ET | 1300 | 4.63 |
02:36 ET | 3000 | 4.62 |
02:38 ET | 3233 | 4.63 |
02:40 ET | 13240 | 4.62 |
02:42 ET | 1862 | 4.62 |
02:44 ET | 4756 | 4.625 |
02:45 ET | 42880 | 4.62 |
02:47 ET | 5362 | 4.62 |
02:49 ET | 6657 | 4.62 |
02:51 ET | 16269 | 4.61 |
02:54 ET | 1972 | 4.61 |
02:56 ET | 9650 | 4.61 |
02:58 ET | 250098 | 4.62 |
03:00 ET | 1400 | 4.62 |
03:02 ET | 26849 | 4.61 |
03:03 ET | 78103 | 4.62 |
03:05 ET | 42052 | 4.625 |
03:07 ET | 42253 | 4.63 |
03:09 ET | 27657 | 4.63 |
03:12 ET | 19346 | 4.63 |
03:14 ET | 165887 | 4.64 |
03:16 ET | 19730 | 4.65 |
03:18 ET | 16865 | 4.65 |
03:20 ET | 11821 | 4.65 |
03:21 ET | 30590 | 4.635 |
03:23 ET | 70599 | 4.6 |
03:25 ET | 9688 | 4.605 |
03:27 ET | 125345 | 4.595 |
03:30 ET | 47039 | 4.6 |
03:32 ET | 77413 | 4.615 |
03:34 ET | 17776 | 4.605 |
03:36 ET | 40335 | 4.605 |
03:38 ET | 11315 | 4.6 |
03:39 ET | 1150890 | 4.57 |
03:41 ET | 93787 | 4.545 |
03:43 ET | 61014 | 4.55 |
03:45 ET | 55653 | 4.555 |
03:48 ET | 22496 | 4.5599 |
03:50 ET | 50387 | 4.545 |
03:52 ET | 47801 | 4.555 |
03:54 ET | 83740 | 4.54 |
03:56 ET | 169439 | 4.54 |
03:57 ET | 68136 | 4.535 |
03:59 ET | 608015 | 4.52 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.7B | -13.1x | --- |
SpringWorks Therapeutics Inc | 2.7B | -7.1x | --- |
Xenon Pharmaceuticals Inc | 2.8B | -13.6x | --- |
Structure Therapeutics Inc | 2.5B | -17.2x | --- |
IDEAYA Biosciences Inc | 2.8B | -18.1x | --- |
MoonLake Immunotherapeutics | 2.5B | -52.9x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -13.1x |
Price/Sales (TTM) | 5,235.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.